曹玉娟, 王德林, 刘承伟, 杜芳, 郝龙英, 曹凤, 李伟伟, 赵聪. 伊立替康或奥沙利铂联合卡培他滨治疗结直肠癌伴肝转移的临床研究[J]. 中国肿瘤临床, 2014, 41(9): 593-596. DOI: 10.3969/j.issn.1000-8179.20140225
引用本文: 曹玉娟, 王德林, 刘承伟, 杜芳, 郝龙英, 曹凤, 李伟伟, 赵聪. 伊立替康或奥沙利铂联合卡培他滨治疗结直肠癌伴肝转移的临床研究[J]. 中国肿瘤临床, 2014, 41(9): 593-596. DOI: 10.3969/j.issn.1000-8179.20140225
shu
CAO Yujuan, WANG Delin, LIU Chengwei, DU Fang, HAO Longying, CAO Feng, LI Weiwei, ZHAO Cong. Clinical research on oxaliplatin or irinotecan plus capecitabine for colorectal liver metastasis treatment[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 41(9): 593-596. DOI: 10.3969/j.issn.1000-8179.20140225
Citation: CAO Yujuan, WANG Delin, LIU Chengwei, DU Fang, HAO Longying, CAO Feng, LI Weiwei, ZHAO Cong. Clinical research on oxaliplatin or irinotecan plus capecitabine for colorectal liver metastasis treatment[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 41(9): 593-596. DOI: 10.3969/j.issn.1000-8179.20140225
shu

伊立替康或奥沙利铂联合卡培他滨治疗结直肠癌伴肝转移的临床研究

Clinical research on oxaliplatin or irinotecan plus capecitabine for colorectal liver metastasis treatment

    摘要
  • 摘要:
      目的  研究分析伊立替康联合卡培他滨及奥沙利铂联合卡培他滨治疗晚期结直肠癌伴肝转移患者的疗效和不良反应。
      方法  入选结肠癌伴肝转移患者125例，随机分成两组，其中治疗组63例，对照组62例，两组均给予卡培他滨1 000 mg/m2，每日2次，1~14 d，治疗组给予伊立替康150 mg/m2+0.9%氯化钠注射液250 mL，1 d静脉滴注，滴注1.5 h；对照组给予奥沙利铂130 mg/m2，1 d。随访的主要内容为无肿瘤进展生存时间（PFS）、中位生存时间（MST）、短期疗效和不良反应等。
      结果  治疗组的ORR、DCR分别为33.3%、66.7%；对照组ORR、DCR分别为35.5%、70.9%；两组比较差异无统计学意义（P>0.05）。治疗组和对照组的中位总生存期分别为14、12个月，相应的中位无进展生存期分别为5、4个月，两组比较差异无统计学意义（P>0.05）；两组Ⅲ、Ⅳ级药物不良反应主要为血液学毒性、消化道反应和手足综合症等，其治疗组的腹泻发生率明显高于对照组，差异有统计学意义（P < 0.05）；不良反应能得到有效控制，未影响化疗进程。
      结论  伊立替康联合卡培他滨和奥沙利铂联合卡培他滨治疗晚期结直肠癌伴肝转移患者的疗效较好，不良反应无明显增多，患者耐受良好，值得临床推广应用。

     

    Abstract:
      Objective  This study aims to evaluate the clinical effect and adverse reactions of oxaliplatin or irinotecan plus capecitabine treatment for colorectal liver metastases.
      Methods  Data from 125 cases of colorectal liver metastasis patients were continuously enrolled and randomized into two groups, i.e., 63 in group one (treatment group) and the other 62 in group two (the control group). Capecitabine was administered at 1 000 mg/m2 doses, twice a day from d1 to d14, to all patients. Irinotecan was administered at 150 mg/m2 in d1 to group one, and oxaliplatin was administered at 130 mg/m2 in d1 to group two. The drug administration cycle lasted for 21 days in both regimens, with at least 6 administration cycles. The total course was for 6 months at most. The therapeutic efficacy, median progression-free survival time, median survival time, short-term clinical effect, and adverse drug reaction were monthly determined.
      Results  The overall response rates and disease control rates were 33.3% and 66.7% in group one, respectively, and 35.5% and 70.9% in group two, respectively, with no significant differences between the groups (P>0.05). The median survival time and median progression-free survival time were 14 months and 5 months in group one, respectively, and 12 months and 5 months in group two, with no significant differences between the two groups (P>0.05). The level-Ⅲ and -Ⅳ adverse drug reactions mainly include hematological toxicity, gastrointestinal reactions, and hand-foot syndrome. The diarrhea frequency is obviously higher in group one than in group two, and the difference between the two groups is statistically significant (P < 0.05). No significant differences were observed in the other adverse reactions between the groups (P>0.05).
      Conclusion  The Oxaliplatin or Irinotecan plus Capecitabine treatment is effective for colorectal liver metastases, which enhances survival rate and reduces patient suffering because of it has less side effects and good tolerance. The treatment must be further generalized and clinically applied.

     

    • HTML全文
    • 参考文献(17)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回